Data and analytics company, GlobalData, has revealed that it believes new launches into the epinephrine injection device market will have the potential to completely transform the space.
epinephrine
For the past decade, the epinephrine injection market has been dominated by Mylan with its EpiPen, with no generic versions and few comparable alternatives available for patients. However, Sandoz and Teva have entered the market through partnerships and may cause a huge shift in the field.